NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis $4.74 -0.37 (-7.24%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.59▼$5.1950-Day Range$4.43▼$6.6052-Week Range$4.10▼$11.30Volume55,801 shsAverage Volume62,658 shsMarket Capitalization$46.90 millionP/E RatioN/ADividend YieldN/APrice Target$44.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Hookipa Pharma alerts: Email Address Hookipa Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside842.3% Upside$44.67 Price TargetShort InterestHealthy0.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.56) to ($4.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector324th out of 910 stocksPharmaceutical Preparations Industry139th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHookipa Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Hookipa Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.35% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently decreased by 71.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOOK. Previous Next 2.8 News and Social Media Coverage News SentimentHookipa Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest3 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hookipa Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to decrease in the coming year, from ($2.56) to ($4.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hookipa Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Hookipa Pharma Stock (NASDAQ:HOOK)HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More HOOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOOK Stock News HeadlinesAugust 30, 2024 | globenewswire.comHOOKIPA Pharma Announces Board of Directors ChangesAugust 28, 2024 | globenewswire.comHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 11, 2024 | finance.yahoo.comHOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss ExpectationsAugust 10, 2024 | markets.businessinsider.comBuy Rating and Price Target Increase for Hookipa Pharma Amid Clinical and Financial ProgressAugust 10, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | theglobeandmail.comSquamous Cell Carcinoma Drugs Pipeline 2024 | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, ModernaAugust 10, 2024 | finance.yahoo.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 8, 2024 | globenewswire.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial HealthJuly 26, 2024 | markets.businessinsider.comOptimistic Outlook for Hookipa Pharma’s Oncology Pipeline Prompts Buy RatingJuly 23, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 22, 2024 | globenewswire.comHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 8, 2024 | globenewswire.comHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock SplitJuly 1, 2024 | globenewswire.comHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIVJune 4, 2024 | globenewswire.comHOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual MeetingMay 30, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual MeetingSee More Headlines Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$44.67 High Stock Price Target$60.00 Low Stock Price Target$24.00 Potential Upside/Downside+842.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net Margins-93.16% Pretax Margin-92.85% Return on Equity-36.81% Return on Assets-23.18% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$52.16 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book0.66Miscellaneous Outstanding Shares9,895,000Free Float9,568,000Market Cap$46.90 million OptionableOptionable Beta0.84 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Joern Aldag (Age 60)Pres, CEO & Director Mr. Daniel Pinschewer (Age 44)Founder & Chief Scientific Officer Dr. Reinhard Kandera (Age 50)CFO & Director Mr. Anders Lilja Ph.D. (Age 46)Sr. VP of Technical Devel. Mrs. Nina WaibelCommunications & Investor Relations Mang.Key CompetitorsGritstone bioNASDAQ:GRTSNeon TherapeuticsNASDAQ:NTGNRigel PharmaceuticalsNASDAQ:RIGLOmerosNASDAQ:OMERZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 83,800 shares on 8/9/2024Ownership: 3.055%Acadian Asset Management LLCBought 108,844 shares on 8/6/2024Ownership: 10.011%View All Institutional Transactions HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? Hookipa Pharma's stock was trading at $8.10 at the beginning of the year. Since then, HOOK shares have decreased by 41.5% and is now trading at $4.74. View the best growth stocks for 2024 here. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) released its earnings results on Thursday, August, 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.08. The company had revenue of $1.29 million for the quarter, compared to analysts' expectations of $5.68 million. Hookipa Pharma had a negative net margin of 93.16% and a negative trailing twelve-month return on equity of 36.81%. When did Hookipa Pharma's stock split? Hookipa Pharma's stock reverse split on the morning of Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Hookipa Pharma IPO? Hookipa Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager. Who are Hookipa Pharma's major shareholders? Top institutional shareholders of Hookipa Pharma include Acadian Asset Management LLC (10.01%) and Renaissance Technologies LLC (3.05%). Insiders that own company stock include Jorn Aldag and Reinhard Kandera. View institutional ownership trends. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC) and Alector (ALEC). This page (NASDAQ:HOOK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts